title: Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.
abstract: OBJECTIVE
  To determine the efficacy of (90)Y [DOTA(0), D-Phe(1), Tyr(3)]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs).
  
  
  METHODS
  The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response.
  
  
  RESULTS
  Median PFS in pancreatic and small bowel NETs was 25 and 28 months, respectively, and median OS was 42 and 38.5 months, respectively. No intergroup differences in median OS (p = 0.945) or PFS (p = 0.174) were found, also after adjustment for tumor origin, secretory status and grade, and patient's gender.
  
  
  CONCLUSIONS
  (90)Y-DOTATATE may have similar efficacy in pancreatic and small bowel NETs. Better WHO performance status at baseline seems to be associated with more favorable outcomes.
authors.affiliation: Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Rogowski
authors.affiliation: Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Wachuła
authors.affiliation: Department of Endocrinology, Medical University of Gdansk, Gdansk, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Lewczuk
authors.affiliation: Department of Nuclear Medicine & PET, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: John R
authors.initials: JR
authors.lastname: Buscombe
authors.affiliation: Department of Radiology & Diagnostic Imaging, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
authors.forename: Nina
authors.initials: N
authors.lastname: Seklecka
authors.affiliation: Department of Radiology & Diagnostic Imaging, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
authors.forename: Artur
authors.initials: A
authors.lastname: Sankowski
authors.affiliation: Faculty of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.
authors.forename: Jarosław B
authors.initials: JB
authors.lastname: Ćwikła
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000401:mortality; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: C539274:90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D015282:Octreotide
keywords: 90Y-DOTATATE therapy; GEP-NET; clinical and radiological response